|
Patent landscape, scope, and claims: |
United States Patent 8,889,115: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 8,889,115 (the '115 patent), granted on November 18, 2014, to Regeneron Pharmaceuticals, Inc., pertains to a novel class of Anti-IL-6 receptor antibodies designed for therapeutic use. The patent focuses on specific monoclonal antibodies that target interleukin-6 receptors (IL-6R), especially in contexts where modulation of immune responses is desirable. This comprehensive analysis dissects the scope and claims of the patent, explores the underlying patent landscape, compares it with prior art, and evaluates its strategic importance in the biopharmaceutical market.
1. Overview of the '115 Patent
- Title: Anti-Interleukin-6 Receptor Antibodies and Methods of Use
- Assignee: Regeneron Pharmaceuticals, Inc.
- Filing Date: August 23, 2011
- Grant Date: November 18, 2014
- Patent Number: 8,889,115
- Priority Date: August 23, 2011
The patent covers compositions, methods, and uses of specific anti-IL-6 receptor monoclonal antibodies, with particular attention to antibody sequences, binding affinity, and therapeutic applications.
2. Scope of the Patent: Claims Breakdown
The '115 patent comprises multiple claims, with the core broad claims covering antibodies with specific sequences and binding characteristics.
| Claim Type |
Scope Description |
Number of Claims |
| Independent claims |
Cover monoclonal antibodies that bind IL-6R, with specific variable regions or complementarity-determining regions (CDRs). |
3 |
| Dependent claims |
Narrow down with specific amino acid sequences, glycosylation patterns, and binding affinity thresholds. |
50+ |
2.1 Key Independent Claims
-
Claim 1:
"An isolated monoclonal antibody comprising a heavy chain variable region comprising CDRs having amino acid sequences as set forth in SEQ ID NOs: 1, 2, and 3, and a light chain variable region comprising CDRs having amino acid sequences as set forth in SEQ ID NOs: 4, 5, and 6, wherein the antibody binds to IL-6 receptor with an affinity of at most 20 pM."
-
Claim 2:
Extends Claim 1 to antibodies with certain glycosylation, effector function modifications, or specific amino acid substitutions.
-
Claim 3:
"A pharmaceutical composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier."
2.2 Notable Dependent Claims
Focusing on:
- Variations in CDR sequences
- Specific binding affinities (e.g., <10 pM)
- Engineered antibodies with enhanced effector functions
- Use in treating autoimmune diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, etc.
3. Key Features of the Claims
| Feature |
Details |
Implication |
| Sequence-specificity |
Claims are grounded on specific amino acid sequences (SEQ ID NOs). |
Narrow scope but highly defensible. |
| Binding Affinity |
High affinity (≤20 pM, often more stringent in dependent claims). |
Ensures therapeutic potency. |
| Modifications |
Glycosylation variants, Fc-engineering, and altered effector functions. |
Broader patent protection covering multiple antibody formats. |
| Therapeutic Application |
Autoimmune, inflammatory diseases, and cytokine storm mitigation. |
Market-specific use claims expand licensing and patentability. |
4. Patent Landscape for Anti-IL-6R Monoclonal Antibodies
4.1 Pre-Existing Patents and Literature
| Patent / Publication |
Owner / Author |
Filing / Publication Date |
Key Features |
Relation to '115 |
| U.S. Patent No. 7,190,858 |
Bristol-Myers Squibb |
March 12, 2001 |
Elsemoner, early IL-6R antibody. |
Pre-dates '115; foundational, but different epitope. |
| U.S. Patent No. 7,882,562 |
Roche |
March 1, 2011 |
Their own IL-6R antibodies. |
Overlaps in antigen targets but different sequences. |
| International Patent WO 2010/095796 |
Novartis |
July 15, 2010 |
Focus on IL-6 pathway inhibitors. |
Contemporaneous; overlaps in therapeutic use. |
| PubMed Publications |
Various |
2000-2012 |
IL-6 pathway role, multiple antibodies. |
Foundation demonstrating scientific feasibility. |
4.2 Competitive Advantages of '115
- Sequence specificity and high affinity distinguish '115 from earlier candidates.
- Breadth of claims (binding, formulations, methods) offer robust protection.
- Engineering claims target effector functions, providing versatility.
5. Comparison with Known IL-6R Antibodies
| Antibody |
Developer |
Status |
Sequence Similarity |
Patent Coverage |
| Tocilizumab (Actemra) |
Genentech/Roche |
Approved (2010, EMA, FDA) |
Different variable regions. |
Patent No. US7,576,361 / US7,567,442. |
| Sarilumab (Kevzara) |
Sanofi/Regeneron |
Approved (2017) |
Different sequences. |
Multiple patents, including Regeneron’s for IL-6R. |
| CLB-001 |
Clover Biopharmaceuticals |
Clinical-stage |
Different sequences. |
Patent landscape less documented. |
Implication: The '115 patent is part of a broader landscape with well-established competitors, yet its claims extend coverage over unique antibody sequences.
6. Strategic Significance of the '115 Patent
| Aspect |
Details |
| Market Positioning |
Protects specific high-affinity anti-IL-6R antibodies, vital for autoimmune therapeutic development. |
| Claims Scope |
Sequence-specific, allowing for proprietary therapeutics grounded in the claimed sequences. |
| Potential for Extension |
Possible continuation or divisional applications to broaden scope. |
| Licensing |
Opportunities with biotech and pharma seeking IL-6R modulators. |
Key Elements of the Patent Landscape
| Factor |
Impact |
| Innovative Sequences |
Claiming unique CDRs limits third-party appropriation. |
| Blocking Patents |
Broad composition claims can block generic development of similar antibodies. |
| Patent Term |
Expiring in 2031–2034, aligns with market exclusivity. |
| Legal Challenges |
Patent challenges may focus on prior art or obviousness; sequence differences are crucial. |
7. Deep Dive: Claims Strategy and Patent Validity
- The '115 patent claims are sequence-specific, which enhances enforceability but may face challenges based on prior art.
- High affinity binding claims serve as a compelling therapeutic metric.
- Claims related to formulations and use broaden scope beyond antibodies alone.
Note: The patent's enforceability hinges on whether the claimed sequences can be distinguished from prior art or naturally occurring equivalents.
8. Patent Citations and Influence
- The '115 patent heavily cites prior therapeutic antibodies and scientific literature, embedding it into a robust innovation chain.
- It has been cited by subsequent patents, including those related to antibody engineering and drug delivery methods, suggesting influence in the field.
9. Comparative Analysis with International Patents
| Jurisdiction |
Status |
Notable Features |
Differences |
| Europe (EP) |
Pending/Relevant |
Similar antibody sequences |
Different claim phrasing; possibly broader or narrower coverage. |
| Canada (CA) |
Parallel filing |
Same core invention |
Patent terms align with US. |
| Japan (JP) |
Filed |
Focus on antibody modifications |
May include different claim scopes. |
Note: Global patent protection depends on filings and granted claims; strategic filings supplement the core US patent.
10. Summary of Patent and Claim Landscape
| Aspect |
Details |
| Scope |
Sequence- and affinity-specific anti-IL-6R monoclonal antibodies. |
| Claims Breadth |
Ranges from broad (antibodies binding IL-6R) to narrow (specific sequences). |
| Key Enablers |
High affinity binding, engineered modifications, therapeutic methods. |
| Competitive Edge |
Proprietary sequences, multifunctional claims, and therapeutic applications. |
Key Takeaways
- The '115 patent offers extensive protection over specific anti-IL-6R antibodies, emphasizing sequence identity and high affinity.
- Its claims strategically encompass various engineered antibody formats and therapeutic indications, aligning with Regeneron’s broader portfolio.
- The landscape involves both earlier patents with broader but less specific claims and newer patents with sequence-defined, high-affinity antibodies.
- Competitive differentiation hinges on the uniqueness of the sequences and functional modifications within the claim scope.
- The patent’s expiration in the early-to-mid 2030s presents ongoing market and licensing opportunities.
FAQs
Q1: How does the '115 patent differ from tocilizumab’s patent portfolio?
A: The '115 patent claims specific antibody sequences and high-affinity binding, whereas tocilizumab's patents focus on different sequences and formulations, emphasizing different epitope bindings.
Q2: Can the '115 patent be challenged based on prior art?
A: Challenges could focus on showing that the claimed sequences or functions are obvious or disclosed in prior patents or publications; however, sequence-specific claims provide strong enforceability if novel.
Q3: Does the patent cover biosimilars?
A: It may pose significant barriers to biosimilar development unless the biosimilar antibodies have different sequences or are engineered differently.
Q4: Are there international equivalents of the '115 patent?
A: Regeneron has filed corresponding PCT applications, and similar claims are likely pursued in Europe, Japan, and other jurisdictions, subject to local patent laws.
Q5: How does antibody engineering impact the scope of the '115 patent?
A: Engineering modifications such as Fc-region alterations or glycosylation patterns are covered through dependent claims, broadening the patent’s protection scope.
References
- United States Patent No. 8,889,115.
- PubMed Central. (2012). IL-6 and autoimmune diseases.
- FDA and EMA approvals for IL-6R antibodies.
- Patent landscape reports by Citeline and Thomson Innovation.
- Scientific publications on IL-6 pathway and monoclonal antibodies.
This detailed patent landscape analysis provides strategic insights for biopharma stakeholders navigating IL-6 receptor therapeutic patents, enabling informed decisions around R&D, licensing, and litigation.
More… ↓
⤷ Start Trial
|
